Newsletter · 2026-07-03 · Ashutosh Agarwal

Medicare Opens First Obesity Coverage as Lilly Hits Record High - Healthcare Podcast Weekly Digest - Week of June 27, 2026

Healthcare was the defensive rotation trade into the second half: the XLV hit 52-week highs, Eli Lilly touched an all-time high near $1,238, Medicare launched its first-ever obesity coverage on July 1, and a record pharma M&A supercycle rolled on. Our synthesis for the week of June 27 to July 3, 2026.

Healthcare Podcast Weekly Digest

Week of June 27, 2026: Medicare Opens First Obesity Coverage as Lilly Hits Record High

1. Opening Summary

Healthcare was the market's defensive rotation trade into the second half, with the XLV hitting 52-week highs and Eli Lilly touching an all-time high near $1,238. Two forces dominated the conversation: the July 1 launch of Medicare's "GLP-1 Bridge" (the first-ever Medicare obesity-drug coverage) and a record pharma M&A supercycle, 32 billion-dollar deals worth ~$123B YTD, both driven by the same ~$300B patent cliff. Managed care sentiment quietly turned from bear to margin-recovery ahead of UnitedHealth's July 16 print, even as new drug-pricing and tariff policy (Section 232, Most-Favored-Nation, a Section 301 probe of Germany) hangs over the group.

2. Key People This Week

3. Hot Topics

GLP-1 / obesity (the week's center of gravity). The Lilly-Novo duopoly (~60/40 in Lilly's favor) faces both a giant catalyst and rising competition. On July 1, CMS launched the 18-month "GLP-1 Bridge" pilot: eligible seniors pay a $50/month copay for Wegovy, Zepbound and the two new oral pills (program runs through end-2027). Lilly hit an all-time high of $1,238 on 6/29 and a ~$1.06T market cap. Novo research says 75% of Medicare seniors prefer pills over injections, making the Foundayo-vs-oral-Wegovy pill battle the new front. On The Important Part, Liz Thomas and Caleb Silver traced the second-order winners (protein/fiber, air fryers, freezers, telehealth) and losers (CPG names like Nestlé and Mondelez).

Eli Lilly. Beyond GLP-1, the bull case is the pipeline (oral weight-loss, Alzheimer's, immunology, oncology, non-opioid pain) and one of the best patent-cliff profiles in the group: tirzepatide (Mounjaro/Zepbound) protected through 2036, and Evaluate projects >$70B in 2032 sales plus >$25B for the Foundayo pill (BioSpace). Leerink's David Risinger raised his target to $1,232 from $1,119 (6/25).

Novo Nordisk. The bear/value debate: down ~45% over the year, ~$2.3B of buybacks, ~9,000 job cuts (~11% of workforce). February's CagriSema head-to-head loss cost 15% in a day ($100B market cap); a later diabetes readout beat expectations as a secondary opportunity (Wall Street Wildlife).

UnitedHealth. Sentiment is repairing ahead of the July 16 Q2 print. BofA raised its target to $475 from $450 (6/24) and Morgan Stanley to $468 from $453 (6/30), arguing UNH "should set a positive tone" for managed care earnings. UNH will also cover Guardant's Shield blood-based colorectal-cancer screen for average-risk adults 45+ effective Aug 1 (~40M members), a "huge" derisking event for Guardant per BTIG (UnitedHealthcare policy).

Drug-spend backdrop. IQVIA's Michael Kleinrock: 2025 US spend hit $606B (+10.6%, after +14.4% in 2024); GLP-1s are only ~1 point of growth, the other 9.6% is spread across oncology, immunology, neurology. List-price sales were $1.363T vs $606B net, a ~$670B gross-to-net spread (The Astonishing Healthcare Podcast).

4. Key Debates

Novo Nordisk: value or value trap?

• Bull: ~10x earnings vs Lilly's ~40x, a dividend, aggressive buybacks and cost cuts, and a still-early global market where "a lot of the bad news is baked in."
• Bear: Structurally second to Lilly on efficacy and pipeline; "a very, very steep downward slope … unless you had an edge, you would not buy this." Trump drug-pricing pressure hits the Danish firm harder than domestic Lilly (Wall Street Wildlife).

Big pharma M&A: smart re-tooling or scrambling?

• Bull: Lilly is "throwing all of the cash from GLP-1s into a ton of deals" to diversify well ahead of its cliff; FDA's softer rare-disease posture is re-rating clinical-stage assets.
• Bear: Merck is the cautionary tale: Keytruda >50% of revenue, patent gone 2028, three deals in 10 months and "little room for error" (Motley Fool).

Managed care: margin recovery or policy overhang?

• Bull: Utilization stabilizing, MCR improving, sell-side targets rising into July 16; UNH re-inventing as a tech/software platform ("the Apple of healthcare," ~$3B AI spend, per Becker's).
• Bear: Medicaid work requirements, OB3 coverage losses, and regulatory scrutiny (a Massachusetts Medicaid-fraud suit) still cloud the multiple.

5. Emerging Themes

• The "GLP-1 economy" spillover: protein/fiber, appliances, alcohol/CPG declines and telehealth as a distinct investable basket, not just a pharma story (The Important Part).
• AI-driven drug discovery and clinical development: synthetic control arms that "halve enrollment" and save ~$1M/day on Phase 3 (The Drug Discovery World Podcast); NVIDIA BioNemo + SandboxAQ virtual screening (Squawk on the Street).
• Payer-as-platform: UnitedHealth monetizing Optum Insight software (claims coding, OR scheduling) and its "COVE" 50M-member command center.
• Defensive rotation into healthcare: GMO's Inker frames US large-cap growth as an "AI bubble," underpinning the flow into healthcare/value (Excess Returns).

6. Deals & M&A Tracker

Full-year pace: 32 billion-dollar deals / ~$123B YTD, strongest since 2019, per Motley Fool; JPM notes XBI at five-year highs with the largest-ever biotech IPO (Kylara) and follow-on (Revolution Medicines), per Making Sense.

7. Regulatory Watch

• Medicare GLP-1 Bridge (July 1): first-ever Medicare obesity coverage; $50/month copay; runs through Dec 31, 2027 (temporary). Leerink pegs eventual annual revenue at ~$1B each for Lilly and Novo.
• Section 301 probe of Germany: Trump administration targeting Germany's domestic pharma price controls as an "unfair practice"; executives reportedly more worried about the German program than tariffs (The Trade Guys).
• Most-Favored-Nation pricing: advancing via voluntary agreements with 17 manufacturers; Section 232 pharma tariffs begin phasing in July 31 (scaling toward a 100% default by September for companies lacking onshoring plans); medical devices currently excluded from Section 232 (The White House, Sidley).
• 340B / OB3: HRSA advancing a broader 340B rebate model; the One Big Beautiful Bill Act raises not-for-profit hospital downgrade risk via Medicaid/ACA coverage losses later this decade (Achieving Health).
• Medicaid work requirements: 25 Democratic-led states + DC sued over CMS's interim final rule (Becker's).
• FDA momentum: approvals this week included AstraZeneca/Daiichi's T-DXd (early HER2+ breast cancer), Ionis's Tryngolza (guidance raised to $875–900M), GSK/Spero oral tebipenem, and generic baloxavir; rare-disease reversals for uniQure and Regenxbio (resubmitting Q3). Lilly's Lebanon, IN plant selected for the FDA PreCheck manufacturing pilot (6/29).

8. Week Ahead

• July 7: Vera Therapeutics PDUFA (atacicept, IgA nephropathy).
• July 16: UnitedHealth Q2 earnings kick off managed care season; the key test of the margin-recovery thesis (watch the medical care ratio).
• July 17: Celcuity PDUFA (gedatolisib, advanced breast cancer).
• July 24: Section 122 10% device tariff set to lapse (barring appeal).
• July 31: First Section 232 pharma tariffs begin phasing in.
• Ongoing: early GLP-1 Bridge uptake data; monitor pill-vs-pill share (Foundayo vs oral Wegovy) and any read-through to Lilly/Novo demand.